Last A$0.14 AUD
Change Today 0.00 / 0.00%
Volume 0.0
MLA On Other Exchanges
Symbol
Exchange
OTC US
As of 9:51 PM 07/23/14 All times are local (Market data is delayed by at least 15 minutes).

medical australia ltd (MLA) Snapshot

Open
A$0.17
Previous Close
A$0.14
Day High
A$0.17
Day Low
A$0.14
52 Week High
01/31/14 - A$0.43
52 Week Low
09/4/13 - A$0.10
Market Cap
14.3M
Average Volume 10 Days
7.8K
EPS TTM
A$-0.03
Shares Outstanding
102.1M
EX-Date
--
P/E TM
--
Dividend
--
Dividend Yield
--
Current Stock Chart for MEDICAL AUSTRALIA LTD (MLA)

Related News

No related news articles were found.

medical australia ltd (MLA) Related Businessweek News

No Related Businessweek News Found

medical australia ltd (MLA) Details

Medical Australia Limited develops, manufactures, and distributes a range of medical devices and equipment for the healthcare industry in Australia, New Zealand, Asia, and the United States. The company’s products primarily include IV systems, safety, blood banking, surgical, and anaesthesia products. It also provides sterile and non-sterile medical plastics for use in surgery and transfusion; and manufactures and supplies products to veterinary surgeons. In addition, the company offers various wall mounted suction devices enabling the aspiration of fluids from patients in clinical applications; oxygen therapy devices for the measurement and distribution of oxygen; and mobile, portable, and manual suction pumps for surgical, emergency, and ward applications. Further, it provides specialty centrifuges for the laboratory, education, and field work for various industries and applications. The company was formerly known as BMDI Tuta Limited and changed its name to Medical Australia Limited in October 2009. Medical Australia Limited was founded in 2001 and is headquartered in Lidcombe, Australia.

27 Employees
Last Reported Date: 09/30/13
Founded in 2001

medical australia ltd (MLA) Top Compensated Officers

General Manager of Finance and Administration
Total Annual Compensation: A$150.0K
General Manager of Corporate Innovation
Total Annual Compensation: A$181.9K
General Manager of Sales & Marketing
Total Annual Compensation: A$150.0K
Compensation as of Fiscal Year 2013.

medical australia ltd (MLA) Key Developments

Medical Australia Limited Announces Consolidated Earnings Results for the Half Year Ended December 31, 2013

Medical Australia Limited announced consolidated earnings results for the half year ended December 31, 2013. For the period, the company reported net loss attributable to owners of the parent entity of AUD 139,464 or 0.26 cents basic and diluted loss per share on sale of goods of AUD 5,287,171 compared to net loss attributable to owners of the parent entity of AUD 296,453 or 0.65 cents basic and diluted loss per share on sale of goods of AUD 4,786,335 for the corresponding period last year. Loss before income tax was AUD 162,429 against AUD 267,360 of prior year period. Net cash used in operating activities was AUD 602,621 against AUD 542,450 of prior year period. Payments for property, plant and equipment were AUD 42,063 against AUD 2,952 of prior year period.

Medical Australia Limited Appoints Jeremy Delk as Director

Medical Australia Limited announced the appointment of Jeremy Delk as a Director of the Company. Jeremy has been responsible for the strategic vision of Medivet and has overseen the operations of that Company since its formation in 2010.

Medical Australia Limited Announces Management Changes

Medical Australia Limited announces a number of changes to its board and senior management. After leading the company through a period of significant change Mark Donnison has taken the decision to step down as Managing Director to pursue other business interests. The Board announced the appointment of Darryl Ellis as Chief Operating Officer. Darryl was educated at the Royal Military College ­ Duntroon, where he developed strong leadership and organisational skills. He has held senior leadership positions at Alcan Australia, CSR, GE Lighting and Assa Abloy. The company also announced that it has strengthened its Board with the appointment of Bruce Hancox as Non- Executive Director. Bruce is an experienced company director and executive with strong financial and M&A skills. During his career, he was both an executive and non-executive director of Brierley Investments Limited. In the healthcare sector, Bruce has served as a non-executive director of Neuren Pharmaceuticals Limited since May 2012. He is a director of Windfall (NZ) Trust which recently invested $2 million into MLA.

 

Stock Quotes

Market data is delayed at least 15 minutes.

Company Lookup
Recently Viewed
MLA:AU A$0.14 AUD 0.00

MLA Competitors

Market data is delayed at least 15 minutes.

Company Last Change
No competitor information is available for MLA.
View Industry Companies
 

Industry Analysis

MLA

Industry Average

Valuation MLA Industry Range
Price/Earnings NM Not Meaningful
Price/Sales 0.9x
Price/Book 1.8x
Price/Cash Flow NM Not Meaningful
TEV/Sales 1.4x
 | 

Sponsored Financial Commentaries

Sponsored Links

Report Data Issue

To contact MEDICAL AUSTRALIA LTD, please visit www.medaust.com. Company data is provided by Capital IQ. Please use this form to report any data issues.

Please enter your information in the following field(s):
Update Needed*

All data changes require verification from public sources. Please include the correct value or values and a source where we can verify.

Your requested update has been submitted

Our data partners will research the update request and update the information on this page if necessary. Research and follow-up could take several weeks. If you have questions, you can contact them at bwwebmaster@businessweek.com.